Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Patent tenofovir alafenamide gilead?
Zemdri plazomicin nce gain exclusivity 2028 patent 2031?
When is the expected fda decision date for apotex's ruxolitinib resubmission?
Drugpatentwatch trametinib?
Allergan's patent for latisse expired?

Vumerity generic name?

See the DrugPatentWatch profile for Vumerity

The generic name for Vumerity is Bafcetimab.

What is Bafcetimab used for?


Bafcetimab is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults [1]. Multiple sclerosis is a chronic disease that affects the central nervous system.

How does Bafcetimab work?


Bafcetimab is an oral disease-modifying therapy that works by modulating immune cell function, which is believed to contribute to the inflammatory processes in MS [1][2]. Specifically, it targets CD20-positive B cells [2].

When will Bafcetimab be available as a generic?


The patent protection for Vumerity is a key factor in determining when a generic version, Bafcetimab, can become available. Information on specific patent expiry dates can be found on resources like DrugPatentWatch.com [3].

What are the side effects of Bafcetimab?


Common side effects reported for Bafcetimab include infusion reactions, upper respiratory tract infections, urinary tract infections, and headache [1].

How does Bafcetimab compare to other MS treatments?


Bafcetimab is one of several disease-modifying therapies available for relapsing forms of MS. Other treatment options include injectables, other oral medications, and infused therapies. The choice of treatment often depends on factors such as the specific type of MS, the patient's medical history, and physician recommendations [1][4].

What is the difference between Vumerity and other oral MS drugs?


Vumerity (Bafcetimab) is an oral sphingosine 1-phosphate (S1P) receptor modulator. Other oral MS medications may belong to different drug classes and work through different mechanisms [1][4]. For instance, some oral medications might be immunosuppressants or immunomodulators, while Bafcetimab's mechanism involves targeting B cells.

Who manufactures Vumerity?


Vumerity is manufactured by Biogen [5].

What clinical trials have been conducted for Bafcetimab?


Clinical trials have evaluated the efficacy and safety of Bafcetimab in treating relapsing forms of MS. Studies like the ASCEND-MS trial have assessed its impact on relapse rates and disability progression [1].

What are the risks associated with Bafcetimab treatment?


Potential risks associated with Bafcetimab include progressive multifocal leukoencephalopathy (PML), liver enzyme elevations, and a reduction in lymphocyte counts [1]. Patients taking Bafcetimab require regular monitoring to detect any adverse events.

What do patients need to know before starting Bafcetimab?


Patients should discuss their full medical history with their healthcare provider, including any history of infections or immune system issues. They should also be aware of the potential side effects and the importance of regular medical check-ups during treatment [1].

Can Bafcetimab be used for primary progressive MS?


Bafcetimab is indicated for relapsing forms of multiple sclerosis and is not typically used for primary progressive MS [1].

What is the dosage of Bafcetimab?


The recommended dosage of Bafcetimab is typically taken orally, twice daily [1].

Where can I find more information about Vumerity patents?


Information regarding the patent status and potential generic availability of Vumerity can be accessed through patent databases and specialized pharmaceutical information websites such as DrugPatentWatch.com [3].

What is the mechanism of action of Bafcetimab?


Bafcetimab is an oral sphingosine 1-phosphate (S1P) receptor modulator. It acts by trapping lymphocytes in the lymph nodes, thereby reducing the number of lymphocytes that can enter the central nervous system and cause inflammation and damage in MS [1][2].

What is the difference between a brand-name drug and a generic drug?


A generic drug, such as Bafcetimab, is a bioequivalent version of a brand-name drug, like Vumerity. Generic drugs have the same active ingredient, dosage form, strength, and route of administration. They are approved by regulatory agencies after the patent protection for the brand-name drug expires, and they are generally available at a lower cost [6].

Sources:
[1] https://www.vumerity.com/
[2] https://www.drugpatentwatch.com/drug/bafcetimab
[3] https://www.drugpatentwatch.com/
[4] https://www.nationalmssociety.org/Treating-MS/Medications
[5] https://www.biogen.com/
[6] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs



Other Questions About Vumerity :

Vumerity company? Vumerity prescribing information? Vumerity used for? How does Vumerity compare to Tecfidera? Vumerity generic? When was vumerity released? Vumerity events?

AI-Drug Label Prescribing Information Alignment Report

18
18%
Grade F

Unsafe

Not Aligned

Patient Risk: High

Summary

Multiple claims incorrectly map “Bafcetimab” to VUMERITY (diroximel fumarate) and state disease/biology mechanisms, side effects, trial details, and administration/monitoring that are not supported by the provided VUMERITY label excerpts. Several statements are therefore unsupported and potentially misleading.

Category Scores

Indication
35
Poor
Dosage
20
Poor
Contraindications
0
Poor
Warnings
30
Poor
Contraindications
0
Poor
Contraindications
0
Poor
AdverseReactions
25
Poor
Administration
10
Poor

Accurate Statements

Potential risks associated with Bafcetimab include progressive multifocal leukoencephalopathy (PML).
VUMERITY Warnings/Precautions (5.2) states PML has occurred in patients treated with dimethyl fumarate (same active metabolite as VUMERITY).
Potential risks associated with Bafcetimab include a reduction in lymphocyte counts.
VUMERITY Warnings/Precautions (5.4) states VUMERITY may decrease lymphocyte counts and provides monitoring guidance.

Unsupported Statements

Bafcetimab is the generic name for Vumerity.
Provided label excerpts for VUMERITY identify active ingredient diroximel fumarate; no label text supports a relationship where “Bafcetimab” is the generic name for VUMERITY.
Bafcetimab is used to treat relapsing forms of multiple sclerosis (MS) in adults.
No label text provided supports “Bafcetimab”; only VUMERITY indication is supported. The mapping from Bafcetimab to VUMERITY is unsupported.
Bafcetimab is an oral disease-modifying therapy.
No label excerpt provided states “Bafcetimab”; the oral route for VUMERITY is supported but only by implication through label dosing (oral capsules), not by the claim wording for Bafcetimab.
Bafcetimab modulates immune cell function.
No label excerpt provided supports this mechanism statement for Bafcetimab.
Bafcetimab targets CD20-positive B cells.
No label excerpt provided supports CD20 targeting; VUMERITY label excerpts provided do not mention CD20.
Common side effects reported for Bafcetimab include infusion reactions.
No adverse reaction list for Bafcetimab is provided; VUMERITY label excerpts provided do not list infusion reactions as common adverse reactions.
Common side effects reported for Bafcetimab include upper respiratory tract infections.
No adverse reaction list in the provided excerpts supports this specific common adverse reaction claim for Bafcetimab.
Common side effects reported for Bafcetimab include urinary tract infections.
No adverse reaction list in the provided excerpts supports this specific common adverse reaction claim for Bafcetimab.
Common side effects reported for Bafcetimab include headache.
No provided label excerpt supports headache as a “common side effect” for Bafcetimab.
Bafcetimab is one of several disease-modifying therapies available for relapsing forms of MS.
The provided label excerpts for VUMERITY do not discuss comparative availability of other therapies.
Vumerity (Bafcetimab) is an oral sphingosine 1-phosphate (S1P) receptor modulator.
Provided label excerpts describe diroximel fumarate; no label excerpt supports S1P receptor modulator characterization or equates it to “Bafcetimab.”
Bafcetimab’s mechanism involves targeting B cells.
No label excerpt provided supports B-cell targeting for VUMERITY (diroximel fumarate) or for Bafcetimab.
Vumerity is manufactured by Biogen.
Manufacturing company is not stated in the provided label excerpts.
Clinical trials have evaluated the efficacy and safety of Bafcetimab in treating relapsing forms of MS.
Label excerpt provided refers to VUMERITY efficacy based on bioavailability studies and clinical studies using dimethyl fumarate in relapsing-remitting MS populations; it does not mention “Bafcetimab” or ASCEND-MS for Bafcetimab.
The ASCEND-MS trial assessed the impact of Bafcetimab on relapse rates and disability progression.
No provided VUMERITY label excerpt mentions ASCEND-MS or that Bafcetimab was studied in that manner.
Potential risks associated with Bafcetimab include liver enzyme elevations.
VUMERITY label discusses liver injury and monitoring of aminotransferase, ALP, and bilirubin, but the claim is framed as a “potential risk” for Bafcetimab without supporting the Bafcetimab↔VUMERITY identity.
Patients taking Bafcetimab require regular monitoring to detect any adverse events.
VUMERITY label provides specific monitoring (CBC with lymphocyte count and liver tests) but the claim is broad (“any adverse events”) and again tied to Bafcetimab without supported mapping.
Bafcetimab is indicated for relapsing forms of multiple sclerosis.
While VUMERITY is indicated for relapsing forms in adults (Section 1), the claim is about Bafcetimab and relies on an unsupported identity mapping.
Bafcetimab is not typically used for primary progressive MS.
Provided label excerpt does not mention “primary progressive MS” in the provided sections, and does not support statements about typical use patterns.
The recommended dosage of Bafcetimab is typically taken orally twice daily.
VUMERITY dosing is 231 mg twice daily starting and 462 mg twice daily maintenance; but the claim is about Bafcetimab without supported identity mapping and omits key titration/maintenance specifics.
Bafcetimab acts by trapping lymphocytes in the lymph nodes.
No label excerpt provided supports this mechanism.
Trapping lymphocytes in the lymph nodes reduces the number of lymphocytes that can enter the central nervous system.
No label excerpt provided supports this mechanism.
Reducing lymphocyte entry into the central nervous system helps reduce inflammation and damage in MS.
No label excerpt provided supports this mechanism.

Contradictions

High

AI Statement
Vumerity (Bafcetimab) is an oral sphingosine 1-phosphate (S1P) receptor modulator.

Label Reference
Label excerpts provided for VUMERITY describe active ingredient diroximel fumarate and do not support S1P receptor modulation; this conflicts with the supplied label basis for VUMERITY.

Important Omissions

VUMERITY-specific dosing titration details (start 231 mg twice daily; increase to 462 mg twice daily after 7 days; possible temporary reductions; resumption within 4 weeks) were not accurately provided for the named agent, and key administration instructions were omitted (swallow whole; avoid high-fat meal; avoid alcohol; optional non-enteric-coated aspirin for flushing).
Importance: Moderate
Important contraindications and interaction: VUMERITY is contraindicated in patients taking dimethyl fumarate and in hypersensitivity to diroximel fumarate/dimethyl fumarate/excipients; this was not addressed.
Importance: High

Safety Assessment

Potential Patient Risk: High
Unsupported/incorrect identity (Bafcetimab = generic for VUMERITY) and unsupported mechanism/class claims (CD20 targeting; S1P receptor modulator) may mislead clinical understanding. Several safety-related claims are ungrounded in the provided label excerpts for VUMERITY.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Most statements are not supported by the provided VUMERITY prescribing information and repeatedly treat “Bafcetimab” as equivalent to VUMERITY despite the label describing diroximel fumarate.

Suggested Improvement
Remove/replace all Bafcetimab-specific identity/mechanism/class and trial claims; instead, reference only VUMERITY label-supported facts (diroximel fumarate; indicated for relapsing forms in adults; dosing and titration; specific contraindications; and label-listed warnings/monitoring).

Drug Brand Mention Assessment

Branding Score
62
Visibility
64
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Vumerity (Bafcetimab) is an oral sphingosine 1-phosphate (S1P) receptor modulator

Core Claims
  • The generic name for Vumerity is Bafcetimab.
  • Vumerity patent protection is a key factor in when a generic version can become available.
  • Vumerity (Bafcetimab) is an oral sphingosine 1-phosphate (S1P) receptor modulator.
Differentiators
  • It is described as an oral S1P receptor modulator.
  • Its mechanism is described as targeting B cells / trapping lymphocytes in lymph nodes.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Biogen 34%
50 #7 No
DrugPatentWatch 28%
50 #5 No
National MS Society 20%
50 #6 No
FDA 30%
50 #9 No